Sanofi-Aventis and Johns Hopkins join forces in asthma
This article was originally published in Scrip
Sanofi-Aventisand the Johns Hopkins University School of Medicine are to jointly discover and develop new methods to treat respiratory diseases, in particular severe asthma and chronic obstructive pulmonary disease, as well as immuno-allergic diseases. Under a three-year agreement, the university's division of allergy and clinical immunology and the French company will work on new target identification, assay development and compound screening, and will collaborate on the design of potential clinical studies and the selection of biomarkers. Sanofi-Aventis already markets the allergy treatment Allegra (fexofenadine HCl) and has a number of NCEs at very early stages of development for asthma.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.